Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD

References

• Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res.9, 887–900 (2000).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Intern. Med.118, 622–629 (1993).
   PubMed Web of Science ®Google Scholar
• Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health2, 113–127 (1999).
   PubMedGoogle Scholar
• Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health7, 79–92 (2004).
   PubMed Web of Science ®Google Scholar
• Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol. Assess.5, 1–157 (2001).
   PubMedGoogle Scholar
• Clauser SB, Bierman AS. Significance of functional status data for payment and quality. Health Care Financ. Rev.24, 1–12 (2003).
   PubMed Web of Science ®Google Scholar
• Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: Conceptual and methodological challenges. Med. Care38, 14–25 (2000).
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Press, Washington, DC, USA (2000).
   Google Scholar
• Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd Edition. Guilford Press, New York, USA (1998).
   Google Scholar
• Barkley RA, DuPaul GJ, McMurray MB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J. Consult. Clin. Psychol.58, 775–789 (1990).
   PubMed Web of Science ®Google Scholar
• Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J. Am. Acad. Child. Adolesc. Psych.30, 752–761 (1991).
   PubMed Web of Science ®Google Scholar
• Brod M, Perwien A, Adler L, Spencer T, Johnston J. Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Primary Psychiatry12, 58–64 (2005).
   Google Scholar
• Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics116, E364–E369 (2005).
   PubMed Web of Science ®Google Scholar
• Hinshaw RD, Melnick SM. Peer relationship in boys with attention deficit hyperactivity disorder with and without comorbid aggression. Dev. Psychopathol.7, 627–647 (1995).
   Web of Science ®Google Scholar
• Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics114, E541–E547 (2004).
   PubMed Web of Science ®Google Scholar
• Matza LS, Rentz AM, Secnik K et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J. Dev. Behav. Pediatr.25, 166–174 (2004).
   PubMed Web of Science ®Google Scholar
• Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J. Am. Acad. Child. Adolesc. Psych.41, 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J. Clin. Psychiatry63, 16–22 (2002).
   PubMed Web of Science ®Google Scholar
• Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin. Ther.25, 3065–3083 (2003).
   PubMed Web of Science ®Google Scholar
• Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy24, 1020–1036 (2004).
   PubMed Web of Science ®Google Scholar
• Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am. J. Health Syst. Pharm.61, 2391–2399 (2004).
   PubMed Web of Science ®Google Scholar
• Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs18, 397–401 (2004).
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry63, 50–55 (2002).
   PubMed Web of Science ®Google Scholar
• Saylor K, Buermeyer C, Sutton V, Faries D, Khan S, Schuh K. An update on the responsiveness and psychometric properties of the life participation scale for ADHD: an adaptive change assessment instrument. Poster presented at the 45th Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU), June 6–9, Boca Raton, FL, USA (2005).
   Google Scholar
• Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J. Dev. Behav. Pediatr.25, 264–271 (2004).
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. Guilford Press, New York, USA (1998).
   Google Scholar
• Gianarris WJ, Golden CJ, Greene L. The Conners’ Parent Rating Scales: a critical review of the literature. Clin. Psychol. Rev.21, 1061–1093 (2001).
   Web of Science ®Google Scholar
• Matza LS, Secnik K, Rentz AM et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual. Life Res.14, 735–747 (2005).
   PubMed Web of Science ®Google Scholar
• Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med. Decis. Making25, 56–70 (2005).
   PubMed Web of Science ®Google Scholar
• Feeny D, Barr RD, Furlong W, Torrance GW, Weitzman S. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Effect of Cancer on Quality of Life. Osaba D (Ed.) CRC Press, Boca Raton, FL, USA (1991).
   Google Scholar
• Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev. Pharmacoeconomics Res.2, 99–108 (2002).
   PubMedGoogle Scholar
• Landgraf JM, Abetz LN, Ware JE. The CHQ User’s Manual. HealthAct, Boston, MA, USA (1999).
   Google Scholar
• Landgraf JM, Maunsell E, Speechley KN et al. Canadian-French, German, and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual. Life Res.7, 433–445 (1998).
   PubMed Web of Science ®Google Scholar
• Rentz AM, Matza LS, Secnik K, Swensen AR, Revicki DA. Psychometric validation of the Child Health Questionnaire (CHQ) in a sample of children and adolescents with attention-seficit/hyperactivity disorder. Qual. Life Res.14, 719–734 (2005).
   PubMed Web of Science ®Google Scholar
• Waters E, Salmon L, Wake M. The parent-form Child Health Questionnaire in Australia: comparison of reliability, validity, structure, and norms. J. Pediatr. Psychol.25, 381–391 (2000).
   PubMed Web of Science ®Google Scholar
• Waters E, Salmon L, Wake M, Hesketh K, Wright M. The Child Health Questionnaire in Australia: reliability, validity and population means. Aust. NZ J. Public Health24, 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics108, E83 (2001).
   PubMed Web of Science ®Google Scholar
• Perwien AR, Faries D, Kratochvil C. Long-term effects of atomoxetine on health-realted quality of life. Poster presented at: American Academy of Child and Adolescent Psychiatry's (AACAP) 51st Annual Meeting, Miami Beach, FL, USA, October 14–19 (2003).
   Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinski MK, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA, USA (1993).
   Google Scholar
• McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care32, 40–66 (1994).
   PubMed Web of Science ®Google Scholar
• Adler L, Kelsey D, Dietrich AP et al. Quality-of-life assessment in atomoxetine-treated adult ADHD patients. Poster presented at: 157th Annual Meeting of the American Psychiatric Association. New York, NY, USA, May 1–6 (2004).
   Google Scholar
• Dupuy HJ. The Psychological General wellbeing (PGWB) Index. In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Wenger NK, Mattson ME, Furberg CD et al. (Eds). Le Jacq Publishing, Washington, DC, USA, 170–183 (1984).
   Google Scholar
• Leonardson GR, Daniels MC, Ness FK et al. Validity and reliability of the general wellbeing schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol. Rep.93, 49–58 (2003).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Zodet MW, Joshua-Gotlib S, Levine D, Crawley JA. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual. Life Outcomes1, 73 (2003).
   Google Scholar
• Saylor KE, Buermeyer CM, Spencer TJ, Barkley RA. Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. J. Clin. Psychiatry63, 23–28 (2002).
   PubMed Web of Science ®Google Scholar
• Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch. Pediatr. Adolesc. Med.156, 384–391 (2002).
   PubMed Web of Science ®Google Scholar
• Brod M, Johnston J, Able S, Swindle R. Adult ADHD Quality of Life: A new measure – the AAQOL. Poster presented at: American Academy of Child and Adolescent Psychiatry's (AACAP) 51st Annual Meeting. Washington, DC, USA, October 19–24 (2004).
   Google Scholar
• Brod M, Johnston J, Able S, Swindle R. Validation of a quality-of-life measure for adult attention-deficit/hyperactivity disorder. Qual. Life Res.15(1) 117–129 (2006).
   PubMed Web of Science ®Google Scholar
• Weiss M, Tannock R, Kratochvil C et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J. Am. Acad. Child. Adolesc. Psych.44, 647–655 (2005).
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Rapport MD, Perriello LM. Teacher rating scales of academic skills: The development of the academic performance rating scale. School Psych. Rev.20, 284–300 (1991).
   Web of Science ®Google Scholar
• Gresham FM, Eliot SN. Social Skills Rating System Manual. American Guidance Service, Circle Pines, MN, USA (1990).
   Google Scholar
• Van der Oord S, Van der Meulen EM, Prins PJ, Oosterlaan J, Buitelaar JK, Emmelkamp PM. A psychometric evaluation of the social skills rating system in children with attention deficit hyperactivity disorder. Behav. Res. Ther.43, 733–746 (2005).
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry159, 1896–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics114, E1–E8 (2004).
   Google Scholar
• Sutton V, Sumner C, Allen AJ, Feng W, Schuh K, Michelson D. Validity, reliability, and responsiveness of the DPREMB-R scale for ADHD. Poster presented at: American Academy of Child and Adolescent Psychiatry's (AACAP) 51st Annual Meeting, Miami Beach, FL, USA, October 14–19 (2003).
   Google Scholar
• Kelsey D, Sutton V, Lewis D, Schuh K, Sumner C, Quintana H. Morning-dosed versus evening-dosed atomoxetine for treating ADHD in children. Poster presented at: 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA, May 21–26 (2005).
   Google Scholar
• Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc. Psychiatry Psychiatr. Epidemiol.27, 78–82 (1992).
   PubMed Web of Science ®Google Scholar
• Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int. J. Psychiatry Med.27, 93–105 (1997).
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry53, 112–120 (2003).
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J. Clin. Psychiatry66, 294–299 (2005).
   PubMed Web of Science ®Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J. Health Econ.5, 1–30 (1986).
   PubMed Web of Science ®Google Scholar
• Torrance GW. Designing and conducting cost-utility analyses. In: Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Edition. Spilker B (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA (1996).
   Google Scholar
• Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur. J. Cancer34, 1181–1186 (1998).
   PubMed Web of Science ®Google Scholar
• Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient–physician communication: A randomized controlled trial. JAMA288, 3027–3034 (2002).
   PubMed Web of Science ®Google Scholar
• Velikova G, Booth L, Smith AB et al. Measuring quality of life in routine oncology practice improves communication and patient wellbeing: A randomized controlled trial. J. Clin. Oncol.22, 714–724 (2004).
   PubMed Web of Science ®Google Scholar
• Prasad S, Sonuga-Barke E, Poole L. Atomoxetine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: effects on broader efficacy. Oral presentation at: International Association for Child & Adolescent Psychiatry and Allied Professionals Annual Meeting. Berlin, Germany, August 22–26 (2004).
   Google Scholar
• Ralston SJ, Lorenzo MJ. ADORE – Attention-deficit hyperactivity disorder observational research in europe. Eur. Child Adolesc. Psychiatry13, I36–I42 (2004).
   Google Scholar
• Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr. Drugs5, 787–794 (2003).
   PubMedGoogle Scholar
• Jensen P. Longer term effects of stimulant treatments for attention-deficit/hyperactivity disorder. J. Atten. Disord.6, S45–S56 (2002).
   Google Scholar
• Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD. J. Am. Acad. Child. Adolesc. Psych.42, 193–200 (2003).
   PubMed Web of Science ®Google Scholar
• Jensen PS, Hinshaw SP, Kraemer HC et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child. Adolesc. Psych.40, 147–158 (2001).
   PubMed Web of Science ®Google Scholar
• Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J. Child Psychol. Psychiatry42, 487–492 (2001).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Brown S et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J. Am. Acad. Child. Adolesc. Psych.41, 262–268 (2002).
   PubMed Web of Science ®Google Scholar
• Abikoff H, McGough J, Vitiello B et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J. Am. Acad. Child. Adolesc. Psych.44, 418–427 (2005).
   PubMed Web of Science ®Google Scholar
• Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J. Am. Acad. Child. Adolesc. Psych.38, 402–409 (1999).
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Newcorn JH, Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child. Adolesc. Psych.44, 915–924 (2005).
   PubMed Web of Science ®Google Scholar
• Moore JL, McAuley JW, Long L, Bornstein R. An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav.3, 92–95 (2002).
   PubMed Web of Science ®Google Scholar